Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

In metastatic stage, therapeutic approach for malignant melanoma is particularly based on performance status, metastatic sites, and BRAF V600 status (BRAF V600E/V600K or V600R (class I BRAF mutations). In most cases, BRAF mutations and NRAS mutations are mutually exclusive to each other. However, so...

Descripción completa

Detalles Bibliográficos
Autores principales: Croix, Manuel, Levallet, Guénaëlle, Richard, Nicolas, Bracquemart, Claire, Tagmouti, Taha, Dompmartin, Anne, Kottler, Diane, L'Orphelin, Jean Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391937/
https://www.ncbi.nlm.nih.gov/pubmed/37533985
http://dx.doi.org/10.1016/j.heliyon.2023.e18420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391937/
https://www.ncbi.nlm.nih.gov/pubmed/37533985
http://dx.doi.org/10.1016/j.heliyon.2023.e18420

Ejemplares similares